Greenwich LifeSciences partners with GBG in Germany for breast cancer trial

Greenwich LifeSciences (GLSI), focused on its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, announced the initiation of clinical sites in Germany. The company has partnered with GBG – German Breast Group -, the largest academic breast cancer research network in Germany, where approximately 38 sites have agreed to participate in FLAMINGO-01. FLAMINGO-01 is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment.